Comments on the three papers by the FDA/CDER research team on the regulatory perspective of the missing data problem

Weichung Joe Shih

doi:10.1002/sim.6895

Comments on the three papers by the FDA/CDER research team on the regulatory perspective of the missing data problem

Weichung Joe Shih

School of Public Health, Biostatistics

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

This communication comments on the three papers by the FDA CDER research team on the regulatory perspective of the missing data problem. The focus is on two topics: causal estimand and sensitivity analysis.

Original language	English (US)
Pages (from-to)	2880-2886
Number of pages	7
Journal	Statistics in Medicine
Volume	35
Issue number	17
DOIs	https://doi.org/10.1002/sim.6895
State	Published - Jul 30 2016

All Science Journal Classification (ASJC) codes

Epidemiology
Statistics and Probability

Access to Document

10.1002/sim.6895

Cite this

@article{3fd2271226954afcba3929b9fdf4b959,

title = "Comments on the three papers by the FDA/CDER research team on the regulatory perspective of the missing data problem",

abstract = "This communication comments on the three papers by the FDA CDER research team on the regulatory perspective of the missing data problem. The focus is on two topics: causal estimand and sensitivity analysis.",

author = "Shih, {Weichung Joe}",

note = "Publisher Copyright: Copyright {\textcopyright} 2016 John Wiley & Sons, Ltd.",

year = "2016",

month = jul,

day = "30",

doi = "10.1002/sim.6895",

language = "English (US)",

volume = "35",

pages = "2880--2886",

journal = "Statistics in Medicine",

issn = "0277-6715",

publisher = "John Wiley and Sons Ltd",

number = "17",

}

TY - JOUR

T1 - Comments on the three papers by the FDA/CDER research team on the regulatory perspective of the missing data problem

AU - Shih, Weichung Joe

PY - 2016/7/30

Y1 - 2016/7/30

N2 - This communication comments on the three papers by the FDA CDER research team on the regulatory perspective of the missing data problem. The focus is on two topics: causal estimand and sensitivity analysis.

AB - This communication comments on the three papers by the FDA CDER research team on the regulatory perspective of the missing data problem. The focus is on two topics: causal estimand and sensitivity analysis.

UR - http://www.scopus.com/inward/record.url?scp=84977483367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977483367&partnerID=8YFLogxK

U2 - 10.1002/sim.6895

DO - 10.1002/sim.6895

M3 - Comment/debate

C2 - 27374355

AN - SCOPUS:84977483367

SN - 0277-6715

VL - 35

SP - 2880

EP - 2886

JO - Statistics in Medicine

JF - Statistics in Medicine

IS - 17

ER -

Comments on the three papers by the FDA/CDER research team on the regulatory perspective of the missing data problem

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this